BRC News

The contrast dye can build up in the body, and its long-term effects are not yet fully understood.

Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product earlier this year.

The drug could have potential to become the first neuroprotective treatment in MS.

The drug aims to prevent a common side effect called Cytokine Release Syndrome.

Most trial participants would previously have been advised to stay on heart medication for life.

The operation was carried out at the National Hospital for Neurology and Neurosurgery at UCLH as part of a clinical trial

Despite progress in treating B-cell acute lymphoblastic leukaemia, there remains a need for safer and more effective therapies.

Full results will be presented at the European Society for Medical Oncology Congress in October.

It could potentially reduce the need for a biopsy before treatment begins.

Ulcerative Colitis has become more common in the UK over the last 25 years and now affects about 0.5% people.

Fatigue is one of the condition’s most common and disabling symptoms.

MPs, experts and families are urging the government to provide interim access to a regulator-approved treatment for Friedreich's Ataxia trialled by UCLH and UCL.

Join us on Thursday 8th October 2026, from 12pm to 4.30pm, to explore cutting-edge health research and innovation happening across UCLH and UCL.

Risk calculators used to estimate a person’s risk of a heart attack or stroke work about as well for predicting certain cancers, according to a new study by UCL researchers.

The phase 2 trial findings were announced at the Alzheimer's Association International Conference 2026.